Wang Xin, Hao Li-Ran, Yue Kai
Thoracic Surgery, Nanyang Central Hospital of Henan Province Nanyang City 473000, Henan Province, China.
Anesthesiology, Nanyang City Orthopaedic Hospital of Henan Province Nanyang City 473002, Henan Province, China.
Int J Clin Exp Med. 2015 Mar 15;8(3):3120-6. eCollection 2015.
The polymorphism of TP53 codon 72, a transversion of G to C (Arg to Pro), has been demonstrated to be associated with the risk for lung cancer. However, individual studies conducted in Chinese have provided conflicting and inconclusive findings. Thus, we performed a meta-analysis by pooling all currently available case-control studies to estimate the effect of TP53 codon 72 Arg/Pro polymorphism on the development of lung cancer in the Chinese population.
MATERIAL/METHODS: Related studies were identified from PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) till 10 October 2014. Pooled ORs and 95% CIs were used to assess the strength of the associations.
A total of 12 case-control studies including 3681 lung cancer cases and 4358 controls were involved in this meta-analysis. Overall, no significant association was found between TP53 codon 72 variation and lung cancer risk when all studies in the Chinese population pooled into this meta-analysis. However, in the subgroup analysis by geographical locations, significantly increased risk was found in the population from North China under all genetic models (Allele model, OR=1.22, 95% CI: 1.04-1.43; Dominant model, OR=1.13, 95% CI: 1.01-1.25; Recessive model, OR=1.41, 95% CI: 1.07-1.87; Homozygous model, OR=1.47, 95% CI: 1.09-1.99; Heterozygous model, OR=1.40, 95% CI: 1.04-1.89).
This meta-analysis provides the evidence that TP53 codon 72 polymorphism may contribute to the lung cancer development in North China and studies with large sample size and gene-gene (gene-environment) interactions are warranted to verify this finding.
TP53基因第72位密码子由G突变为C(由精氨酸变为脯氨酸)的多态性已被证明与肺癌风险相关。然而,在中国进行的个别研究结果相互矛盾且尚无定论。因此,我们通过汇总所有现有病例对照研究进行了一项荟萃分析,以评估TP53基因第72位密码子精氨酸/脯氨酸多态性对中国人群肺癌发生的影响。
材料/方法:从PubMed、Springer Link、Ovid、中国万方数据知识服务平台、中国知网(CNKI)和中国生物医学文献数据库(CBM)中检索截至2014年10月10日的相关研究。采用合并的比值比(OR)和95%可信区间(CI)评估关联强度。
本荟萃分析共纳入12项病例对照研究,包括3681例肺癌病例和4358例对照。总体而言,当将中国人群的所有研究汇总进行此项荟萃分析时,未发现TP53基因第72位密码子变异与肺癌风险之间存在显著关联。然而,在按地理位置进行的亚组分析中,在所有遗传模型下,发现华北人群的风险显著增加(等位基因模型,OR = 1.22,95% CI:1.04 - 1.43;显性模型,OR = 1.13,95% CI:1.01 - 1.25;隐性模型,OR = 1.41,95% CI:1.07 - 1.87;纯合子模型,OR = 1.47,95% CI:1.09 - 1.99;杂合子模型,OR = 1.40,95% CI:1.04 - 1.89)。
这项荟萃分析提供了证据表明TP53基因第72位密码子多态性可能与华北地区肺癌的发生有关,需要开展大样本量以及基因-基因(基因-环境)相互作用的研究来验证这一发现。